A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Inclusion criteria

• Participants who have at least a 12-week history before Screening Visit of CRSsNP and confirmed by endoscopy at Visit 1 (Screening).
• Participants must have a NCS of ≥2 at Visit 1 (Screening Visit) and Visit 2 (Baseline; average score in the week prior to randomization).
• Participants must have sTSS (nasal congestion [NC], anterior/posterior rhinorrhea, facial pain/pressure) ≥5 at Visit 1 (Screening) and at Visit 2 (Baseline; average score in the week prior to randomization).
• Participants who have at least 1 of the 3 following features:

• Previous sinonasal surgery for CRS, including but not limited to fenestrated endoscopic sinus surgery and balloon sinuplasty.
• Received medical treatment with systemic corticosteroids (SCS) to treat symptoms of CRS as defined by any dose and duration within 1 year of Screening Visit or intolerance/contraindication to SCS.
• Received a course of antibiotics to treat symptoms of CRS within 1 year before the Screening Visit.
• Participants who have a blood eosinophil count ≤750 cells/microliter (μL) at Visit 1 (Screening).
• Participants who have bilateral inflammation of paranasal sinuses in the CT scan performed during Screening and bilateral ethmoid and/or maxillary opacification before randomization as confirmed by the central reader.
• Participants who have a SNOT-22 score of ≥20 at Visit 1 (Screening) and Visit 2 (Baseline).
• Participants who have received a stable daily dose regimen of MFNS for at least 4 weeks before Visit 2 (Baseline).

Exclusion criteria

• Diagnosis of unilateral or bilateral chronic rhinosinusitis with nasal polyps (CRSwNP).
• Clinical diagnosis of cystic fibrosis (CF) or primary ciliary dyskinesia.
• Scheduled sinus surgery at any time during the study.
• Participants who have had nasal surgery within 4 weeks before Visit 1 (Screening) and during the Screening Period.
• Significant oral maxillofacial structural abnormalities or severe septal deviation.
• Participants with radiological suspicion or confirmed invasive fungal rhinosinusitis, odontogenic sinusitis, osteomas, or nasal tumors.
• Participants with acute change in symptoms consistent with acute rhinosinusitis.
• Participants with seasonal allergic rhinitis whose symptoms coincide with the treatment period of the study.
• Participants with moderate to severe atopic dermatitis requiring treatment with high potency topical steroids or topical calcineurin inhibitors or biologics.
• Clinical diagnosis of Papillon-Lefèvre syndrome.

Note: Other inclusion/exclusion criteria may apply.